Studies of trends in the consequences of heroin use, such as overdoses, are important. However, these studies do not provide information about underlying trends in the population burdens of heroin use and related disorders in US adults or in the characteristics and patterns of use among heroin users. For such trends, national survey data are needed. The National Survey on Drug Use and Health (NSDUH) is a potential source of such information. However, other than brief summaries, 1, 16, 17 little has been published from NSDUH on trends in heroin use. Apart from the NSDUH, no studies known to us have addressed time trends in heroin consumption among US representative samples, including change over time in the prevalence of lifetime heroin use and heroin use disorders overall or patterns and characteristics of heroin use and related disorders among users (eg, age at onset, use frequency, disorder severity, types of abuse, or dependence symptoms endorsed). Using US adult national surveys conducted during 2001-2002 and 2012-2013, we addressed the following questions. First, did prevalence of lifetime heroin use and related disorders increase? Second, did demographic characteristics associated with lifetime heroin use and heroin use disorders change? Third, did patterns, severity, and substance comorbidity of heroin use and related disorders change?
Methods

Study Design and Participants
We obtained data from the following 2 nationally representative face-to-face household surveys of adults 18 years and older residing in households and group quarters 18, 19 : the 2001-2002 National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) (n = 43 093), and the 2012-2013 NESARC-III (n = 36 309). NESARC and NESARC-III used similar multistage probability sampling designs with oversampling for Hispanic, black, and (in NESARC-III) Asian individuals. [19] [20] [21] Survey weights were used to adjust for differential probabilities of participant selection and household and person-level nonresponse and adjusted sample margins to match key demographic distributions (eg, age, sex, and race) of each target population. 19 ,22 NESARC and NESARC-III used computerassisted interviews and highly trained interviewers. Response rates in NESARC (60.1%) and NESARC-III (81.0%) were comparable to those of other national surveys. 23, 24 Interviewer quality assurance methods were similar across surveys. 22 The Respondents gave written informed consent and were compensated for participation.
Assessments Heroin Use and DSM-IV Use Disorder
The National Institute on Alcohol Abuse and Alcoholism Alcohol Use Disorder and Associated Disabilities Interview Schedule IV (AUDADIS-IV), a fully structured diagnostic interview designed for use by nonclinician interviewers after structured training, was used to assess substance use and psychiatric disorders according to DSM-IV criteria. In NESARC-III, the AUDADIS-5 was used to assess substance use and DSM-IV 25 and DSM-5 26 criteria for substance use disorders.
Lifetime heroin use (ever vs never used heroin) was measured in both surveys and was included as a binary (yes or no) variable in our analyses. The reliability and validity of AUDADIS DSM-IV substance use disorder diagnoses have been well documented. [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] We combined abuse and dependence because the criteria reflect a single disorder rather than 2 conditions. 41 Symptom items (n = 30) that assessed DSM-IV heroin use disorder (abuse and dependence) in the NESARC and NESARC-III were virtually identical. However, 4 items were slightly reworded and 1 abuse item appeared in the NESARC but not the NESARC-III, whereas a different abuse item appeared in the NESARC-III but not the NESARC. Comparisons between DSM-IV heroin use disorder diagnoses with and without the additional questions yielded virtually identical prevalences (NESARC: 0.69% vs 0.68%; NESARC-III: 0.21% vs 0.21%), with corresponding near perfect or perfect concordance (κ = 0.998 and κ = 1.00, respectively), suggesting that these trivial differences could not account for the substantial differences in prevalence between the surveys. 
Statistical Analysis
Data were analyzed from February 2 to September 15, 2016. We combined NESARC and NESARC-III data to conduct repeated cross-sectional analyses, as was done previously to examine other trends in these surveys. 22, 43, 44 We added a variable representing the survey from which the participant was included. Weighted prevalences were produced for full samples and by subgroups. We conducted 3 sets of analyses. First, using separate models for each heroin outcome (lifetime use or lifetime use disorder) to estimate whether prevalences differed between surveys, we modeled survey year as associated with the outcome. Second, with logistic regression models, we tested associations between demographic variables and heroin use or heroin use disorder. Then, to test whether associations between demographic characteristics and the outcomes differed between surveys, we added an interaction term between the survey year and each demographic variable to all models. To assess differential associations on the prevalence scale, we first estimated prevalence differences between strata of the demographic variables (eg, male and female respondents) within each survey. We tested whether these prevalence differences differed between surveys (eg, male and female respondents in NESARC vs male and female respondents in NESARC-III) using pairwise t tests for independent samples. We estimated these prevalences and their SEs from model-predicted logodds, back-transformed to the prevalence scale. 
Discussion
In the 2012-2013 NESARC-III, 1.61% of US adults had ever used heroin, and 0.69% had ever met criteria for a heroin use dis- Despite the decreased risk for heroin use disorder among users, the large increase in users led to an overall increased prevalence of heroin use disorder in the adult population.
The increases that we show in lifetime heroin use and use disorder are consistent with increases in heroin outcomes in several other studies during the same period. The NSDUH showed a 62.5% increase in the rates of heroin use and a 90% increase (from 1.0 to 1.9 per 1000 population) in the rates of past-year heroin use disorder. 17 In addition, mortality associ- creased more than among women. Similar results were reported using NSDUH data. 16, 57 Changes in the heroin sex gap are consistent with those for marijuana. 58, 59 Changes in exposure to risk factors for heroin may explain the widening heroin sex gap. For example, men may have been more affected by economic stressors than women (eg, low manufacturing employment rates 60 leading to greater increases in male heroin use). Although heroin use is now more widespread among individuals of all socioeconomic strata (Table 1 and eTable 1 in the Supplement) and among those with stronger bonds to social institutions, 61 relative increases in heroin use and use disorder across time were greater among less educated and poorer individuals. These trends are concerning because increases in the prevalence of heroin use and use disorder have been occurring among vulnerable individuals who have few resources to overcome problems associated with use. 62, 63 No differences in prevalence of heroin use were found by age. However, in NESARC-III, the prevalence of heroin use disorders was significantly higher among younger than older aged (≥45 years) groups. The proportion of heroin users with a lifetime heroin use disorder decreased between the 2 surveys, primarily owing to decreases in DSM-IV abuse criteria. Some subgroups of heroin users (those with greater resources and infrequent users) might be less likely to develop milder abuse symptoms. However, if the prevalence of heroin use continues to increase, the numbers of those with heroin use disorders will likely increase as well.
No NESARC participants and 2.1% of NESARC-III participants reported that heroin was the only illicit drug they had used. Although this result may seem surprising, it is consistent with reports that some individuals transition from use of POs to heroin with no history of other drug use besides POs. 49 
Limitations and Strengths
NESARC and NESARC-III lacked biological testing for substances and excluded homeless and incarcerated individuals. Including We focused on associations with lifetime use, lifetime disorder, and patterns of lifetime disorder across time, which are important population parameters, particularly for very rare conditions such as heroin outcomes in the general population. For very rare conditions (eg, any heroin outcome in the general population), examining lifetime cases may be the only way to determine demographic and clinical correlates and patterns of use during the life course, which simply cannot be estimated from small numbers of survey participants with current heroin use or use disorders. Furthermore, lifetime heroin use prevalence represents the burden on a population of a highly risky behavior for which sequelae often persist even after cessation of use of that particular drug.
Limitations are balanced by numerous strengths, including use of AUDADIS in both surveys and assessment of more than 79 000 participants. Study data provide unique information on time trends during a period when changes associated with heroin use patterns occurred (eg, increase in white users, lower prevalence of heroin use disorder in recent years). 13, 49 Study findings provide context for further investigation of how demographic, clinical, and other risk factors for heroin use and heroin use disorders may have changed over time. Continued monitoring of such time trends is an important public health priority.
Conclusions
The prevalences of heroin use and use disorder have increased significantly in the US adult general population since the beginning of this millennium. Of note, increases have been greatest among men, white individuals, those with low income and educational levels, and, for heroin use disorder, younger individuals. To curb the heroin epidemic, particularly among younger adults, collective prevention and intervention efforts may be most effective. 71 Promising examples include expansion of access to medication-assisted treatment (including methadone hydrochloride, buprenorphine hydrochloride, or injectable naltrexone hydrochloride), educational programs in schools and community settings, 72 overdose prevention training in concert with comprehensive naloxone hydrochloride distribution programs, 73 and consistent use of prescription drug monitoring programs that implement best practices by prescribers. 74, 75 Efforts may be most efficient if concentrated in states acutely affected by the opioid epidemic, as noted in President Obama's Comprehensive Addiction Recovery Act signed in July 2016. 71 Although many par- b DSM-IV heroin use disorder refers to DSM-IV drug abuse or dependence.
